F-18 FDG PET/CT 测量的 SUVmax 在初诊小细胞肺癌患者中的预后价值有限。
Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
机构信息
Department of Nuclear Medicine, Pusan National University Hospital, Busan, Republic of Korea.
出版信息
Oncol Res Treat. 2015;38(11):577-85. doi: 10.1159/000441289. Epub 2015 Oct 21.
BACKGROUND
The purpose of this study was to evaluate the prognostic value of the maximum standard uptake value (SUV max) measured by 18-F fluoro-2-deoxy-d-glucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in newly diagnosed small cell lung cancer (SCLC) patients.
METHODS
We reviewed the medical records of newly diagnosed SCLC patients who were given a histological diagnosis from June 2008 to June 2014. 82 patients who satisfied the inclusion criteria were enrolled for final analysis (male n = 75, female n = 7). The relationship between SUV max and overall survival (OS) and progression-free survival (PFS) was evaluated.
RESULTS
Median follow-up was 25.0 months (range 11.6-55.5 months). The median OS was 11.2 months (range 1.6-55.5 months), and the median PFS was 6.1 months (range 0.9-55.5 months). Survival analysis showed no statistical differences in OS and PFS between high and low SUV max groups.
CONCLUSION
This study does not support the use of SUV max of pretreatment F-18 FDG PET/CT scans as a prognostic tool for patients with SCLC.
背景
本研究旨在评估 18-F 氟-2-脱氧-D-葡萄糖（F-18 FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）测量的最大标准摄取值（SUV max）在新诊断的小细胞肺癌（SCLC）患者中的预后价值。
方法
我们回顾了 2008 年 6 月至 2014 年 6 月期间接受组织学诊断的新诊断 SCLC 患者的病历。符合纳入标准的 82 例患者被纳入最终分析（男性 n=75，女性 n=7）。评估 SUV max 与总生存期（OS）和无进展生存期（PFS）的关系。
结果
中位随访时间为 25.0 个月（范围 11.6-55.5 个月）。中位 OS 为 11.2 个月（范围 1.6-55.5 个月），中位 PFS 为 6.1 个月（范围 0.9-55.5 个月）。生存分析显示，高 SUV max 组和低 SUV max 组的 OS 和 PFS 无统计学差异。
结论
本研究不支持将 F-18 FDG PET/CT 扫描治疗前 SUV max 用于预测 SCLC 患者的预后。
Zotero 插件